10 Hidden-Gem AI Stocks to Buy Right Now

Ten small to mid-cap companies are highlighted for effectively integrating AI into specific operational niches across diverse sectors, including healthcare, insurance, and enterprise software. These firms apply existing AI technologies to solve real-world problems, generating measurable value and competitive advantages, thus offering higher risk-reward profiles compared to established tech giants. For growth investors, these "hidden gems" represent a next wave of AI investment opportunities, though company-specific risks necessitate careful consideration and diversification.

Analysis

The analysis highlights an investment thesis centered on ten small to mid-cap companies that are applying existing artificial intelligence technologies to create defensible niches, rather than competing with mega-cap firms like Nvidia and Microsoft in foundational model development. These firms operate across diverse sectors such as healthcare (Oscar Health), insurance (Lemonade), enterprise software (Freshworks, PagerDuty, Sprinklr, Amplitude), and biotech (Recursion Pharmaceuticals), offering a higher risk-reward profile. The core value proposition is the measurable ROI or competitive advantage AI provides, such as PagerDuty's ability to shorten IT incident response times or Lemonade's use of AI bots for underwriting. However, significant company-specific risks are present. For instance, Freshworks shows mid-teens revenue growth but struggles with profitability and was notably absent from a correlated 'top 10' buy list. Recursion Pharmaceuticals, with a $2 billion market cap and a partnership with Nvidia, represents a high-beta play entirely dependent on future clinical trial success. Similarly, Lemonade's model hinges on its ability to prove AI can stabilize loss ratios, while BigBear.ai's growth is subject to the volatility of government defense contracts. The overall strategy proposed is diversification across these 'hidden gems' to capture the upside of practical AI application while mitigating idiosyncratic risks.

Key Decisions for Investors

• Investors interested in the applied AI theme should consider a basket approach, diversifying capital across several of the profiled small-to-mid-cap names to mitigate single-stock risks such as clinical trial failures or poor underwriting performance.
• Careful due diligence on company-specific execution is critical; key metrics to monitor include loss ratios for Lemonade (LMND), contract flow for BigBear.ai (BBAI), and clinical trial progress for Recursion Pharmaceuticals (RXRX).
• Despite being profiled, Freshworks (FRSH) warrants caution due to its elusive profitability and its explicit exclusion from the analyst team's '10 best stocks' list, which signals potential underperformance relative to other opportunities.
• For those with a high risk tolerance, Recursion Pharmaceuticals (RXRX) and Nerdy (NRDY) represent targeted bets on AI transforming the biotech and education sectors, respectively, but their speculative nature requires accepting the potential for significant volatility.